HUE031567T2 - Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására - Google Patents
Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására Download PDFInfo
- Publication number
- HUE031567T2 HUE031567T2 HUE08732592A HUE08732592A HUE031567T2 HU E031567 T2 HUE031567 T2 HU E031567T2 HU E08732592 A HUE08732592 A HU E08732592A HU E08732592 A HUE08732592 A HU E08732592A HU E031567 T2 HUE031567 T2 HU E031567T2
- Authority
- HU
- Hungary
- Prior art keywords
- ésének
- solution
- protein
- reagent
- acid
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 50
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 50
- 150000004676 glycans Chemical class 0.000 title claims abstract description 48
- 238000000746 purification Methods 0.000 title claims description 61
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 93
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 51
- 230000020477 pH reduction Effects 0.000 claims abstract description 34
- 238000001914 filtration Methods 0.000 claims abstract description 29
- 230000008569 process Effects 0.000 claims abstract description 28
- 238000011026 diafiltration Methods 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 239000006166 lysate Substances 0.000 claims abstract description 13
- 230000001413 cellular effect Effects 0.000 claims abstract description 10
- 238000010979 pH adjustment Methods 0.000 claims abstract 3
- 238000013060 ultrafiltration and diafiltration Methods 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 43
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 230000002934 lysing effect Effects 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 239000012465 retentate Substances 0.000 claims description 14
- 239000013592 cell lysate Substances 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 230000003205 diastolic effect Effects 0.000 claims description 6
- -1 silylene oxide lead diester Chemical class 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003245 coal Substances 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000010802 sludge Substances 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- KVGOXGQSTGQXDD-UHFFFAOYSA-N 1-decane-sulfonic-acid Chemical compound CCCCCCCCCCS(O)(=O)=O KVGOXGQSTGQXDD-UHFFFAOYSA-N 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- VDUFOKXWMKHHHS-UHFFFAOYSA-N S1SCC=C1.[Na] Chemical compound S1SCC=C1.[Na] VDUFOKXWMKHHHS-UHFFFAOYSA-N 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000009849 deactivation Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 206010016531 fetishism Diseases 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 230000000887 hydrating effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 125000005429 oxyalkyl group Chemical group 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- 229940124733 pneumococcal vaccine Drugs 0.000 claims 1
- 239000012070 reactive reagent Substances 0.000 claims 1
- 229940071089 sarcosinate Drugs 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 229920001864 tannin Polymers 0.000 claims 1
- 239000001648 tannin Substances 0.000 claims 1
- 235000018553 tannin Nutrition 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000000670 limiting effect Effects 0.000 abstract description 3
- 230000002101 lytic effect Effects 0.000 abstract 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 abstract 2
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 abstract 2
- 239000004793 Polystyrene Substances 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 33
- 238000001179 sorption measurement Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000004140 cleaning Methods 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 206010021198 ichthyosis Diseases 0.000 description 11
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 10
- 239000003610 charcoal Substances 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000011109 contamination Methods 0.000 description 5
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006229 carbon black Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QRDZSRWEULKVNW-UHFFFAOYSA-N 6-hydroxy-2-oxo-1h-quinoline-4-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)=CC(=O)NC2=C1 QRDZSRWEULKVNW-UHFFFAOYSA-N 0.000 description 1
- 244000003377 Allium tuberosum Species 0.000 description 1
- 235000005338 Allium tuberosum Nutrition 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101001051916 Escherichia coli (strain K12) Molybdenum cofactor guanylyltransferase Proteins 0.000 description 1
- 101100012841 Escherichia coli (strain K12) fetA gene Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 108050003242 Kelch-like protein 41 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 241001477893 Mimosa strigillosa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241001181114 Neta Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- IKLLMTFCGFPKAD-UHFFFAOYSA-M P(=O)([O-])(O)O.[Na+].C(C=1C(C(=O)O)=CC=CC1)(=O)O Chemical compound P(=O)([O-])(O)O.[Na+].C(C=1C(C(=O)O)=CC=CC1)(=O)O IKLLMTFCGFPKAD-UHFFFAOYSA-M 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000785684 Sander lucioperca Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001415849 Strigiformes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 101150010415 eat-5 gene Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 101150033534 lysA gene Proteins 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89661607P | 2007-03-23 | 2007-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE031567T2 true HUE031567T2 (hu) | 2017-07-28 |
Family
ID=39712482
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08732592A HUE031567T2 (hu) | 2007-03-23 | 2008-03-20 | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| HUE11194173A HUE039169T2 (hu) | 2007-03-23 | 2008-03-20 | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| HUE18177128A HUE059085T2 (hu) | 2007-03-23 | 2008-03-20 | Streptococcus pneumoniae tokpoliszacharidok elõállítására szolgáló rövidített tisztítási eljárás |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11194173A HUE039169T2 (hu) | 2007-03-23 | 2008-03-20 | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| HUE18177128A HUE059085T2 (hu) | 2007-03-23 | 2008-03-20 | Streptococcus pneumoniae tokpoliszacharidok elõállítására szolgáló rövidített tisztítási eljárás |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8652480B2 (enExample) |
| EP (3) | EP2436700B8 (enExample) |
| JP (5) | JP5688902B2 (enExample) |
| KR (2) | KR101500771B1 (enExample) |
| CN (1) | CN101663327B (enExample) |
| AU (1) | AU2008231041B2 (enExample) |
| BR (1) | BRPI0809212B8 (enExample) |
| CA (1) | CA2681570C (enExample) |
| CL (2) | CL2008000831A1 (enExample) |
| CO (1) | CO6251324A2 (enExample) |
| CR (1) | CR11041A (enExample) |
| DK (3) | DK3406635T3 (enExample) |
| EC (1) | ECSP099652A (enExample) |
| ES (3) | ES2922132T3 (enExample) |
| GT (1) | GT200900249A (enExample) |
| HN (1) | HN2009001965A (enExample) |
| HU (3) | HUE031567T2 (enExample) |
| IL (1) | IL201106A (enExample) |
| MX (1) | MX2009010221A (enExample) |
| MY (1) | MY150927A (enExample) |
| NI (1) | NI200900172A (enExample) |
| NZ (1) | NZ580134A (enExample) |
| PL (3) | PL2129693T3 (enExample) |
| PT (3) | PT3406635T (enExample) |
| RU (1) | RU2516340C2 (enExample) |
| SI (3) | SI3406635T1 (enExample) |
| UA (1) | UA99278C2 (enExample) |
| WO (1) | WO2008118752A2 (enExample) |
| ZA (1) | ZA200906625B (enExample) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE031567T2 (hu) * | 2007-03-23 | 2017-07-28 | Wyeth Llc | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
| GB0818453D0 (en) * | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| US11065323B2 (en) * | 2008-10-27 | 2021-07-20 | Glaxosmithkline Biologicals Sa | Purification method |
| US8795689B2 (en) * | 2008-12-18 | 2014-08-05 | Wyeth Llc | Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight |
| US20100160622A1 (en) * | 2008-12-18 | 2010-06-24 | Wyeth Llc | Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| EP3238742A1 (en) | 2009-06-22 | 2017-11-01 | Wyeth LLC | Immunogenic compositions of staphylococcus aureus antigens |
| BRPI1011753B8 (pt) | 2009-06-22 | 2021-05-25 | Wyeth Llc | conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
| WO2011145108A2 (en) * | 2010-05-15 | 2011-11-24 | Serum Institute Of India Ltd. | Purification of capsular polysaccharides |
| JP5944480B2 (ja) * | 2011-03-22 | 2016-07-05 | セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド | 多糖を調製するための新規な方法 |
| CN102660602B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| CN102660603B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 一种快速纯化细菌荚膜多糖的方法 |
| CN102660601B (zh) * | 2012-04-17 | 2015-10-28 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| US9650411B2 (en) * | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
| CN104781413B (zh) * | 2012-09-07 | 2018-01-23 | Sk化学公司 | 用于具有肺炎球菌血清型的荚膜多糖的生产方法 |
| WO2014053612A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic composition |
| US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
| US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
| US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
| US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
| US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
| US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
| SG11201508999UA (en) | 2013-07-12 | 2015-11-27 | Emd Millipore Corp | A method of determining virus removal from a sample containing a target protein using activated carbon |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| NZ759686A (en) | 2014-01-21 | 2023-07-28 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| HUE064837T2 (hu) * | 2014-01-21 | 2024-05-28 | Pfizer | Streptococcus pneumoniae kapszuláris poliszacharidok és azok konjugátumai |
| HK1223273A1 (zh) | 2014-01-21 | 2017-07-28 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| KR102149760B1 (ko) | 2015-01-15 | 2020-08-31 | 화이자 인코포레이티드 | 폐렴구균 백신에서 사용하기 위한 면역원성 조성물 |
| WO2016178123A1 (en) | 2015-05-04 | 2016-11-10 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US20180223326A1 (en) * | 2015-06-18 | 2018-08-09 | The Research Foundation For Microbial Diseases Of Osaka University | Method For Measuring Complement-Dependent Bactericidal Function With Respect To Pneumococci |
| PE20180657A1 (es) | 2015-07-21 | 2018-04-17 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
| CN105131139B (zh) * | 2015-07-31 | 2018-02-13 | 兰州生物制品研究所有限责任公司 | 一种肺炎链球菌荚膜多糖的纯化方法 |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| JP7001687B2 (ja) | 2016-08-05 | 2022-02-04 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物 |
| BR112019001995A2 (pt) | 2016-08-05 | 2019-05-07 | Sanofi Pasteur, Inc. | composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| AU2017388891C1 (en) | 2016-12-30 | 2025-04-17 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| WO2018144438A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| EP4656208A2 (en) | 2017-01-31 | 2025-12-03 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| MX2019009869A (es) | 2017-02-24 | 2019-10-02 | Merck Sharp & Dohme | Formulaciones de vacunas de conjugado de neumococos. |
| AU2018225099B2 (en) | 2017-02-24 | 2024-08-22 | Merck Sharp & Dohme Llc | Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| AU2018280272C1 (en) | 2017-06-10 | 2021-05-06 | Inventprise, Inc. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
| JP7111799B2 (ja) | 2017-07-05 | 2022-08-02 | インベントプライズ リミテッド ライアビリティ カンパニー | 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製 |
| US10702596B2 (en) | 2017-07-05 | 2020-07-07 | Inventprise, Llc | Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography |
| WO2019050813A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| PL3678654T3 (pl) | 2017-09-07 | 2024-12-16 | Merck Sharp & Dohme Llc | Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe |
| MX394767B (es) | 2017-09-07 | 2025-03-24 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
| CN107936128B (zh) * | 2017-11-22 | 2020-07-03 | 成都欧林生物科技股份有限公司 | 一种简便有效的细菌疫苗纯化方法 |
| NZ765694A (en) | 2017-12-06 | 2024-03-22 | Merck Sharp & Dohme Llc | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| IL276230B2 (en) | 2018-02-05 | 2024-01-01 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| JP7288451B2 (ja) | 2018-02-05 | 2023-06-07 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体－タンパク質複合体組成物 |
| WO2019212842A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| CN112074293B (zh) | 2018-04-30 | 2025-07-11 | 默沙东有限责任公司 | 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法 |
| EP3788143B1 (en) | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| EA202190168A1 (ru) | 2018-07-04 | 2021-06-07 | Ваксайт, Инк. | Усовершенствования в иммуногенных конъюгатах |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| US12018134B2 (en) * | 2018-07-19 | 2024-06-25 | Glaxosmithkline Biological Sa | Processes for preparing dried polysaccharides |
| JP7585203B2 (ja) | 2018-12-12 | 2024-11-18 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用 |
| US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| US20220265803A1 (en) | 2019-07-31 | 2022-08-25 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US12473379B2 (en) * | 2019-09-06 | 2025-11-18 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| AU2021224078B2 (en) | 2020-02-21 | 2024-01-18 | Pfizer Inc. | Purification of saccharides |
| CN116075517A (zh) * | 2020-06-12 | 2023-05-05 | 巴斯夫欧洲公司 | 改进的发酵液的脱矿化与诸如寡糖的精细化学品的纯化 |
| JP7630603B2 (ja) | 2020-08-10 | 2025-02-17 | インベントプライズ・インコーポレイテッド | 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン |
| AU2021332183B2 (en) | 2020-08-26 | 2025-12-18 | Pfizer Inc. | Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| KR20230097160A (ko) | 2020-11-04 | 2023-06-30 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| WO2022101745A2 (en) | 2020-11-10 | 2022-05-19 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022249106A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| GB2614916A (en) | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| CN120265317A (zh) | 2022-11-22 | 2025-07-04 | 辉瑞公司 | 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| JP2025541706A (ja) | 2022-12-01 | 2025-12-23 | ファイザー・インク | 肺炎球菌コンジュゲートワクチン製剤 |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121038808A (zh) | 2023-03-30 | 2025-11-28 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20240390471A1 (en) | 2023-05-18 | 2024-11-28 | Merck Sharp & Dohme Llc | Compounds and adjuvant formulations useful in pneumococcal vaccines |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2861695D1 (en) | 1977-11-07 | 1982-04-29 | Ciba Geigy Ag | Process for the manufacture of fluorinated cationic compounds and their use as surfactants |
| CA1115210A (en) * | 1977-11-28 | 1981-12-29 | Dennis J. Carlo | Pneumococcal vaccine |
| US4221906A (en) * | 1979-03-19 | 1980-09-09 | American Cyanamid Company | Stabilization of pneumococcal polysaccharides |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| FR2495939B1 (fr) | 1980-12-11 | 1985-10-11 | Merieux Inst | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| JPS6170994A (ja) * | 1984-09-14 | 1986-04-11 | Daikin Ind Ltd | 環状（１→２）−β−Ｄ−グルカンの製法 |
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| US5714354A (en) * | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
| RU2087156C1 (ru) * | 1995-06-22 | 1997-08-20 | Леонид Николаевич Падюков | Вакцина против пневмококковой инфекции |
| WO1999032653A1 (en) * | 1997-12-23 | 1999-07-01 | North American Vaccine, Inc. | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines |
| US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| GB0108079D0 (en) * | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US20060228380A1 (en) * | 2005-04-08 | 2006-10-12 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| SI1866342T1 (sl) * | 2005-04-08 | 2019-02-28 | Wyeth Llc | Ločevanje onesnaževalcev od polisaharida streptococcus pneumoniae s postopkom manipulacije pH |
| HUE031567T2 (hu) * | 2007-03-23 | 2017-07-28 | Wyeth Llc | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására |
-
2008
- 2008-03-20 HU HUE08732592A patent/HUE031567T2/hu unknown
- 2008-03-20 KR KR1020097021976A patent/KR101500771B1/ko active Active
- 2008-03-20 DK DK18177128.8T patent/DK3406635T3/da active
- 2008-03-20 NZ NZ580134A patent/NZ580134A/en unknown
- 2008-03-20 PT PT181771288T patent/PT3406635T/pt unknown
- 2008-03-20 MY MYPI20093908 patent/MY150927A/en unknown
- 2008-03-20 AU AU2008231041A patent/AU2008231041B2/en active Active
- 2008-03-20 PL PL08732592T patent/PL2129693T3/pl unknown
- 2008-03-20 WO PCT/US2008/057688 patent/WO2008118752A2/en not_active Ceased
- 2008-03-20 KR KR1020157002150A patent/KR20150021127A/ko not_active Ceased
- 2008-03-20 US US12/052,525 patent/US8652480B2/en active Active
- 2008-03-20 DK DK08732592.4T patent/DK2129693T3/en active
- 2008-03-20 SI SI200832196T patent/SI3406635T1/sl unknown
- 2008-03-20 PT PT87325924T patent/PT2129693T/pt unknown
- 2008-03-20 RU RU2009135485/10A patent/RU2516340C2/ru active
- 2008-03-20 CL CL200800831A patent/CL2008000831A1/es unknown
- 2008-03-20 CA CA2681570A patent/CA2681570C/en active Active
- 2008-03-20 EP EP11194173.8A patent/EP2436700B8/en active Active
- 2008-03-20 HU HUE11194173A patent/HUE039169T2/hu unknown
- 2008-03-20 MX MX2009010221A patent/MX2009010221A/es active IP Right Grant
- 2008-03-20 PL PL18177128.8T patent/PL3406635T3/pl unknown
- 2008-03-20 HU HUE18177128A patent/HUE059085T2/hu unknown
- 2008-03-20 SI SI200831741A patent/SI2129693T1/sl unknown
- 2008-03-20 BR BRPI0809212A patent/BRPI0809212B8/pt active IP Right Grant
- 2008-03-20 JP JP2009554744A patent/JP5688902B2/ja active Active
- 2008-03-20 EP EP18177128.8A patent/EP3406635B1/en active Active
- 2008-03-20 ES ES18177128T patent/ES2922132T3/es active Active
- 2008-03-20 SI SI200831984T patent/SI2436700T1/sl unknown
- 2008-03-20 PL PL11194173T patent/PL2436700T3/pl unknown
- 2008-03-20 DK DK11194173.8T patent/DK2436700T5/en active
- 2008-03-20 UA UAA200909741A patent/UA99278C2/ru unknown
- 2008-03-20 EP EP08732592.4A patent/EP2129693B1/en active Active
- 2008-03-20 ES ES08732592.4T patent/ES2614249T3/es active Active
- 2008-03-20 CN CN200880012946.2A patent/CN101663327B/zh active Active
- 2008-03-20 PT PT111941738T patent/PT2436700T/pt unknown
- 2008-03-20 ES ES11194173.8T patent/ES2677353T3/es active Active
-
2009
- 2009-09-17 HN HN2009001965A patent/HN2009001965A/es unknown
- 2009-09-21 GT GT200900249A patent/GT200900249A/es unknown
- 2009-09-21 NI NI200900172A patent/NI200900172A/es unknown
- 2009-09-22 ZA ZA200906625A patent/ZA200906625B/xx unknown
- 2009-09-22 IL IL201106A patent/IL201106A/en active IP Right Grant
- 2009-09-23 EC EC2009009652A patent/ECSP099652A/es unknown
- 2009-09-23 CR CR11041A patent/CR11041A/es unknown
- 2009-10-20 CO CO09117278A patent/CO6251324A2/es active IP Right Grant
-
2014
- 2014-01-24 US US14/163,863 patent/US8999697B2/en active Active
-
2015
- 2015-01-27 JP JP2015013167A patent/JP2015143225A/ja not_active Withdrawn
- 2015-02-27 US US14/633,141 patent/US9675681B2/en active Active
-
2017
- 2017-03-23 JP JP2017056848A patent/JP6825950B2/ja active Active
- 2017-08-08 CL CL2017002029A patent/CL2017002029A1/es unknown
-
2018
- 2018-11-06 JP JP2018208647A patent/JP2019048844A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014532A patent/JP6872649B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE031567T2 (hu) | Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására | |
| EP2062977B1 (de) | Fucosyltransferase-Gen | |
| ES2651415T3 (es) | Método de producción de un polisacárido capsular que tiene un serotipo neumocócico | |
| DE2441454C3 (de) | Antileukämische proteinhaltige Fraktion und ihre Herstellung | |
| JP2010521972A5 (enExample) | ||
| CN1378592A (zh) | 在无rna酶和有机溶剂的条件下应用切向流过滤来纯化质粒dna的方法 | |
| DE60038664T2 (de) | Genträger | |
| JP5908496B2 (ja) | トランスジェニックイネの子実からヒト血清アルブミンを抽出する方法 | |
| CN104530250A (zh) | 一种纯化肺炎链球菌荚膜多糖的方法 | |
| CN117756958A (zh) | 一种制备肺炎链球菌荚膜多糖或其降解多糖的方法 | |
| CN106978512A (zh) | 用于检测新型竹鼠源阿卡斑病毒的rt‑pcr引物及其试剂盒 | |
| Hemleben-Vielhaben | Characterization of rapidly labelled nucleic acids in tissues of plant seedlings | |
| CN113975408A (zh) | 一种基于非甲基化CpG纳米疫苗、制备方法和应用 | |
| TW202103687A (zh) | Ogg1的粉末化組成物及其用途 | |
| TW202446962A (zh) | 莢膜多醣之純化 | |
| DE2463223C2 (de) | Präzipitat von Polyäthylenoxid und Calcium- oder Magnesium-Ionen und daran adsorbierten Viruspartikeln und seine Verwendung zur Herstellung von Impfstoffen | |
| WO2025245378A1 (en) | Nucleic acid delivery using direct binding of nucleic acids to rbcs | |
| CN119074938A (zh) | 一种用于mRNA递送和表达的核酸组合物及其应用 | |
| KR100484926B1 (ko) | 짧은 단편 ｄｎａ 편자 분리용 아가로스 제조방법 | |
| CN103088131A (zh) | 样品中腐败乳酸菌的pcr 检测方法 | |
| EP1123400A1 (de) | Gen für einen thrombininhibitor aus raubwanzen und protein mit thrombinhemmender wirkung | |
| CN118773279A (zh) | 一种利用青花椒副产物提取细胞穿透肽的方法 | |
| JPS63276493A (ja) | ヒアルロン酸の製造方法 | |
| CN103409409A (zh) | 一种快速提取瓜类基因组dna的方法 | |
| JPS5933227A (ja) | 抗腫瘍活性物質ｒｄ−０１とその製法およびその製剤 |